Darwin Wealth Management’s Corcept Therapeutics CORT Stock Holding History

Darwin Wealth Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$22K	Buy	+191	New	+$20.5K	0.01%	494

Other funds holding CORT

Parallel Advisors San Francisco, California $7.42B AUM 27.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Darwin Wealth Management's CORT Position: Q3 2026 in Review

Darwin Wealth Management opened a new position in Corcept Therapeutics (CORT) in Q3 2026: 191 shares worth $22K. The stake represents 0.01% of the portfolio and ranks #494 among its holdings.

280 funds tracked by Wall St. Rank hold CORT as of Q3 2026.

Darwin Wealth Management held 191 shares of Corcept Therapeutics worth $22K as of Q3 2026.
Corcept Therapeutics was a new Darwin Wealth Management position in Q3 2026.
Corcept Therapeutics made up 0.01% of Darwin Wealth Management's portfolio in Q3 2026, its #494 holding.
280 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.

Based on Darwin Wealth Management's 13F filing for Q3 2026, filed 9 Nov 2026.